
- November 9, 2026Transgene Reports Continued Clinical Progress and Q3 2026 Financial Update
- November 5, 2026First Patient Dosed in Phase 1 Trial Evaluating Transgene’s and BioInvent’s BT-001 in Patients with Rectal Cancer
- November 3, 2026Transgene to Present Preclinical Data on Novel Oncolytic Virus at SITC 2026 Supporting its Potential for Systemic Delivery
- October 5, 2026Transgene Will Present a Poster on Preclinical Data from a Novel Oncolytic Virus at SITC 2026
- October 1, 2026Transgene To Participate in Investor Access
- September 24, 2026Transgene Extends its myvac® Platform, Further Establishing its Position as a Key Player in the Rapidly Emerging Individualized Cancer Immunotherapy Field
- September 8, 2026Transgene and ProBioGen Expand Strategic Partnership with Additional License Agreement for AGE1.CR.pIX Cell Line
- September 2, 2026Transgene and NEC Report 100% Three-Year Disease-Free Survival with TG4050 and Publish Phase 1 Results in Nature Communications
- June 25, 2026Transgene to Present Preclinical Data Demonstrating Robust Protection Against Mpox with its Novel Scalable Cell Line-Derived MVA Vaccine Candidate (TG MVA(TM)) at WCID 2026
- June 22, 2026Transgene Expands myvac® into Non-Small Cell Lung Cancer with TG4070, an Individualized Neoantigen Therapeutic Vaccine
See all press releases